Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 45, Issue 1, 1998, Pages 21-26

  Millar, Andrew W ^a   Brown, Peter D ^a   Moore, Jeff ^a   Galloway, W Alan ^a   Cornish, Alan G ^a   Lenehan, Terence J ^b   Lynch, Kevin P ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

^b MDS Inc   (Canada)

Author keywords

Absorption; Half life; Marimastat; Metalloproteinase inhibitors; Pharmacokinetics; Safety

Indexed keywords

MARIMASTAT; METALLOPROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ENZYME INHIBITION; EOSINOPHILIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PLACEBOS;

EID: 0031882946     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00639.x     Document Type: Article

References (12)

1. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. Trends In Genetics 1990; 6: 121-125.
2. Kleiner DJ, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteinases. Curr Op Cell Biol 1993; 5: 891-897.
3. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Sem Cancer Biol 1990; 1: 99-106.
4. Gordon JL, Drummond, AH, Galloway WA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rheum 1993; 11: S91-94.
5. O'Byrne EM, Parker DT, Roberts ED, et al. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflamm Res 1995; 44: S117-118.
6. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg ML. Enhanced expression of matrilysin, collagenase and stromelysm-1 in gastrointestinal ulcers. Am J Pathol 1996; 148: 519-526.
7. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
8. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma 1995; 12: 833-842.
9. Galardy RE, Cassabone ME, Giese C, et al. Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 1994; 732: 315-323.
10. Macaulay VM, O'Byrne KJ, Saunders MP, et al. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. Br J Cancer 1995; 71: 11 (Abstract).
11. Drummond AH, Beckett P, Bone EA, et al. BB-2516: An orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995; 36: 100 (Abstract).
12. Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokin 1991; 16: 249-255.